PRESS RELEASE – IMMUNOCORE LIMITED

Immunocore wins Financing Deal of the Year at the 12th Annual SCRIP Awards 2016

(Oxford, UK, 1st December 2016) Immunocore Limited, a world-leading biotechnology company developing novel T cell receptor (TCR) based biological drugs to treat cancer, infectious diseases and autoimmune diseases, was awarded Financing Deal of the Year at last night’s SCRIP awards at the Grosvenor House Hotel, Park Lane, London.

2016 has been a stellar year for Immunocore, fuelled by the Company’s record-breaking $320 million series A financing round to advance its lead programme, IMCgp100. The Company used the financing to advance its ImmTAC programmes through clinical development and strengthen its strategic partnerships, including the launch of a Phase I combination therapy trial with MedImmune. Immunocore also expanded its infectious disease pipeline, with data published in the journal Molecular Therapy, demonstrating the potential of novel antiviral drugs to kill HIV-infected cells.

Eliot Forster, Chief Executive Officer of Immunocore, commented: “This award is a tribute to the hard work and commitment of the whole team behind the $320 million Series A financing round and all of Immunocore’s staff, Board and investors. This private capital has enabled Immunocore to continue to work towards bringing our technology to patients, having announced positive clinical data with our lead programme, IMCgp100, in metastatic, uveal and cutaneous melanoma, advanced our strategic partnerships and progressed additional ImmTAC programmes towards the clinic.”

The SCRIP Awards, now in its 12th year, is among the most prestigious in the calendar for the life sciences industry. The Financing Deal of the Year Award seeks to reward successful and creative fundraising by pharma and biotech companies.

- ENDS –

For more information, please contact:

Immunocore
Eliot Forster, Chief Executive Officer
T: +44 (0)1235 438600
E: info@immunocore.com

Consilium Strategic Communications
Mary-Jane Elliott/Jessica Hodgson/Chris Welsh/Laura Thornton
T: +44 (0)203 709 5700
E: Immunocore@consilium-comms.com

Notes for editors
About Immunocore

Immunocore is one of the world’s leading biotechnology companies, with a highly innovative immuno-oncology platform technology called ImmTAC. ImmTAC molecules are a novel class of biologic drugs based on the Company’s proprietary T cell receptor (TCR) technology which have the potential to treat diseases with high unmet medical need including cancer, infectious diseases and autoimmune diseases. Immunocore has a pipeline of wholly-owned and partnered ImmTAC programmes with robust clinical data. In addition to oncology, Immunocore is also developing programmes with its TCR-based platform as potential therapy for HIV and other infectious diseases. Immunocore aims to leverage the utility of its platform across a wide range of indications.

Immunocore’s world-leading science and strong IP position has attracted major pharmaceutical companies including Genentech, GlaxoSmithKline, MedImmune, the biologics division of AstraZeneca, via discovery collaborations, as well as a co-discovery and co-development partnership with Lilly. The Company has also entered into combination trials with its lead programme, IMCgp100 in metastatic melanoma, with MedImmune and Lilly. Founded in 2008 from academic research originating at Oxford University, Immunocore is headquartered outside Oxford with US offices outside Philadelphia, Immunocore now has close to 280 staff. Immunocore’s current investors are well-renowned, leading international institutions including Woodford Investment Management, Malin Corporation, Eli Lilly and Company, RTW Investments, Fidelity Management & Research Company as well as other private shareholders. For more information, please visit www.immunocore.com

About ImmTAC Molecules

Immunocore’s proprietary technology is focused on small protein molecules called ImmTAC (Immune mobilising monoclonal TCRs Against Cancer) molecules that enable the immune system to recognise and kill cancerous cells. Immunocore’s ImmTAC molecules, a new class of drug with ultra-high affinity for intracellular cancer targets, are synthetic, soluble T cell receptors (TCRs) that recognize diseased cells containing disease specific targets. The ImmTAC molecules enable circulating T cells to selectively identify and kill diseased cells. The TCR-based platform is unique in its high specificity and potency, encouraging safety, low cost of goods.

ImmTAC molecules can access up to nine-fold more targets than typical antibody-based therapies, including monoclonal antibodies. TCRs naturally recognise diseased cells and Immunocore’s world-leading competitive advantage is its ability to engineer high affinity TCRs and link them to an antibody fragment that activates a highly potent and specific T cell response to recognise and destroy cancer cells.

ImmTAC molecules has a broad applicability to a wide range of intracellular targets and disease indications including solid tumours, infectious diseases and autoimmune diseases.

Immunocore has a growing internal pipeline of ImmTAC molecules addressing many different cancer types and has developed a broad database of intracellular cancer targets.

About IMCgp100

IMCgp100 is a first-in-class bi-specific biologic known as a T cell redirector. It binds with picomolar affinity, to a melanoma associated peptide, gp100; once bound, IMCgp100 redirects all T cells,
IMCgp100 is the most advanced ImmTAC, and is currently in Phase I/IIa clinical trials for the treatment of late stage melanoma and so far more than 120 subjects have been treated at more than 20 centers internationally. IMCgp100 has been granted Orphan Drug Designation by the US Food and Drug Administration (FDA) for the treatment of uveal melanoma and is a participant in the European Medicines Agency’s (EMA) Adaptive Pathways Pilot Programme.